PSP Omics Center of Acute to Chronic Pain Signatures

PSP 组学中心急性至慢性疼痛特征

• 批准号: 10611136
• 负责人: Jon Jacobs
• 金额: $ 50万
• 依托单位: BATTELLE PACIFIC NORTHWEST LABORATORIES
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-09-01 至 2023-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10611136
• 关键词: Acute; Address; Administrative Supplement; Biological Assay; Clinical Research; Collaborations; Communication; Data; Data Analyses; Development; Elements; Funding; Generations; Goals; Informatics; Investigation; Laboratories; Lead; Mass Spectrum Analysis; Medical center; Metadata; Molecular; Molecular Profiling; Pacific Northwest; Patients; Proteins; Proteomics; Protocols documentation; Sampling; Secure; Standardization; Stream; Time; Universities; Work; base; chronic pain; clinical research site; data streams; experience; high throughput screening; multiple omics; predictive signature; programs; prospective; recruit

PROJECT SUMMARY This administrative supplement is to continue the ongoing support of the PNNL lead Omics Data Generation Center (PNNL-ODGC) within the broader context of the A2CPS consortium. Delays within the A2CPS consortium primarily due to recruitment in the MCC1 and MCC2 clinical site components have facilitated the extension of efforts beyond the planned timeframe of the A2CPS consortium. Though extensive carry-over funds have been secured and will be used to extend the analysis timeframe of the PNNL-ODGC efforts, there still remain gaps in funding based upon current expected recruitment goals, timeframes, and the subsequent proteomic sample analysis needs. Overall, the objective of the PNNL-ODGC remains, which is to develop and implement high throughput proteomics-based assays for quantifying a broad and diverse set of molecular players associated with acute to chronic pain conversion with the goal to develop predictive signatures as well as inform upon relevant molecular mechanisms. This brings together advanced mass spectrometry (MS) proteomics capabilities (Pacific Northwest National Laboratory, PNNL) and high throughput screening capabilities (Luminex Core at University of Pittsburgh Medical Center, UPMC) to accurately detect and quantify a broad spectrum of primary and secondary marker targets as well as provide a robust proteomic discovery element for further investigation.

项目摘要 本行政补充文件将继续为PNNL牵头的组学数据生成提供持续支持 中心（PNNL-ODGC）在A2CPS联盟的更广泛的背景下。A2CPS内的延迟 主要由于MCC 1和MCC 2临床研究中心组成部分的招募， 在A2CPS联盟计划的时间范围之外延长工作。虽然大量结转 资金已经到位，将用于延长PNNL-ODGC工作的分析时间表， 根据目前的预期征聘目标、时间框架和随后的时间框架， 蛋白质组学样品分析需要。总的来说，《国家无核武器区发展计划》的目标仍然是发展和 实施基于高通量蛋白质组学测定以定量一组广泛且多样的分子 与急性到慢性疼痛转换相关的玩家，目标是开发预测签名， 作为相关分子机制的信息。这汇集了先进的质谱（MS） 蛋白质组学能力（太平洋西北国家实验室，PNNL）和高通量筛选 能力（匹兹堡大学医学中心，UPMC的Luminex核心），以准确地检测和定量 广泛的一级和二级标志物靶点，并提供了强大的蛋白质组学发现 进一步调查的元素。